Could β-Lactam Antibiotics Block Humoral Immunity?

Area of Science:

• Immunology
• Microbiology
• Biochemistry

Background:

• Beta-lactam antibiotics can negatively impact immune responses, including vaccination and immunotherapy.
• Metallo-beta-lactamases (hMBLs) are human enzymes, with SNM1A, B, and C proteins crucial for DNA repair and immune system development (e.g., SNM1C/Artemis in V(D)J recombination).
• Mutations in SNM1C/Artemis lead to severe combined immunodeficiency.

Purpose of the Study:

• To investigate the hypothesis that beta-lactam antibiotics can inhibit human metallo-beta-lactamase (hMBL) proteins, specifically SNM1C/Artemis.
• To explore the potential for beta-lactam-induced transient immunodeficiency in humans.

Main Methods:

• Literature review of in silico, in vitro, and in vivo evidence.
• Analysis of conserved catalytic sites in hMBLs and SNM1 family proteins.
• Examination of in vitro studies showing beta-lactam inhibition of SNM1A, B, and SNM1C/Artemis.

Main Results:

• Beta-lactam antibiotics, such as third-generation cephalosporins and ampicillin, have demonstrated inhibitory effects on SNM1A, B, and SNM1C/Artemis proteins in vitro.
• The catalytic sites of hMBLs, particularly the SNM1 family, are highly conserved.
• Evidence suggests a potential mechanism for beta-lactam antibiotics to interfere with human immune function.

Conclusions:

• Beta-lactam antibiotics may inhibit key human metallo-beta-lactamase proteins involved in DNA repair and immune system function.
• This inhibition could lead to transient immunodeficiency, impacting cellular immunity and increasing susceptibility to infections.
• Further understanding of this interaction could inform new therapeutic strategies in oncology, immunology, and infectious diseases.